Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer
出版年份 2018 全文链接
标题
Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer
作者
关键词
-
出版物
ONCOGENE
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-09
DOI
10.1038/s41388-018-0429-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
- (2018) Giuseppe Giaccone et al. LANCET ONCOLOGY
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Chromatin and Cytoskeletal Remodeling by SETD2
- (2016) In Young Park et al. CELL
- PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair
- (2016) E-B Choi et al. ONCOGENE
- LAMC2 enhances the metastatic potential of lung adenocarcinoma
- (2015) Y W Moon et al. CELL DEATH AND DIFFERENTIATION
- Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
- (2015) Paolo Maione et al. Therapeutic Advances in Medical Oncology
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Identification of functional cooperative mutations of SETD2 in human acute leukemia
- (2014) Xiaofan Zhu et al. NATURE GENETICS
- H3K36 Histone Methyltransferase Setd2 Is Required for Murine Embryonic Stem Cell Differentiation toward Endoderm
- (2014) Yuanliang Zhang et al. Cell Reports
- Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas
- (2013) Adam M. Fontebasso et al. ACTA NEUROPATHOLOGICA
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fanconi Anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments
- (2010) Lisa A. Kachnic et al. CANCER LETTERS
- Histone Methyltransferase Gene SETD2 Is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma
- (2010) Gerben Duns et al. CANCER RESEARCH
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
- (2010) Gillian L. Dalgliesh et al. NATURE
- The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters
- (2009) W Al Sarakbi et al. BMC CANCER
- LY303511 Enhances TRAIL Sensitivity of SHEP-1 Neuroblastoma Cells via Hydrogen Peroxide-Mediated Mitogen-Activated Protein Kinase Activation and Up-regulation of Death Receptors
- (2009) K. Shenoy et al. CANCER RESEARCH
- Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells
- (2008) Manrong Jiang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Cyclic AMP Response Element-Binding Protein Overexpression: A Feature Associated with Negative Prognosis in Never Smokers with Non-Small Cell Lung Cancer
- (2008) H.-S. Seo et al. CANCER RESEARCH
- Activation of the RAF/Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Mediates Apoptosis Induced by Chelerythrine in Osteosarcoma
- (2008) R. Yang et al. CLINICAL CANCER RESEARCH
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started